Business Context and Reporting Period
Company: Skye Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 6, 2025
Reporting Period: Event-based report regarding the release of clinical trial data.
Key Financial Metrics
This filing is a Regulation FD disclosure regarding clinical trial results and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material event reported is the issuance of a press release on October 6, 2025, announcing topline data from the CBeyond Phase 2a clinical trial for the Company's drug candidate, Nimacimab. The data covers both monotherapy and combination treatment arms.
Guidance, Outlook, and Management Commentary
- Management Action: The Company intends to host a conference call and live webcast on October 6, 2025, at 8:00 a.m. E.T. to discuss the trial results.
- Disclosure Status: The information, including the press release (Exhibit 99.1), is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
- Outlook: No specific financial guidance or future operational outlook is provided in this document beyond the immediate discussion of trial data.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific efficacy and safety data from the Nimacimab Phase 2a trial.
- Listen to the conference call held on October 6, 2025, for management's interpretation of the topline data.
- Verify the next steps for the Nimacimab development program as outlined in the press release.
- Check subsequent filings for any updates on the Company's cash position or financing needs resulting from the trial outcomes.